Since its inception in 2018, Inspira Technologies OXY B.H.N. Ltd has focused on developing the INSPIRA ART100, an innovative extracorporeal oxygenation device offering an alternative to traditional mechanical ventilators. The company has incurred growing operating losses driven by R&D and commercial preparation, supported by equity raises amid liquidity constraints. FDA 510(k) clearance for cardiopulmonary bypass indications and integration with the HYLA blood sensor mark pivotal regulatory milestones underpinning early commercialization efforts. While strategic OEM partnerships and global distribution agreements have begun unlocking market access, sustained growth hinges on further clinical validation, broader regulatory approvals, and overcoming market adoption hurdles entrenched by incumbent ventilation technologies.